A61K 38/4893
Botulinum neurotoxin
Official title: {Botulinum neurotoxin (3.4.24.69)}
A61K38/4893 (Botulinum neurotoxin) appears on 699 US grants and 1,248 published applications in this corpus.
Search patents in A61K- Granted patents
- 699
- Published applications
- 1,248
- Assignees
- 247
- Inventors
- 867
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 1 | 0 |
| 2000 | 5 | 0 |
| 2001 | 11 | 12 |
| 2002 | 17 | 25 |
| 2003 | 12 | 14 |
| 2004 | 11 | 45 |
| 2005 | 15 | 43 |
| 2006 | 8 | 33 |
| 2007 | 20 | 43 |
| 2008 | 26 | 50 |
| 2009 | 11 | 45 |
| 2010 | 32 | 55 |
| 2011 | 23 | 32 |
| 2012 | 32 | 68 |
| 2013 | 44 | 46 |
| 2014 | 36 | 62 |
| 2015 | 48 | 50 |
| 2016 | 49 | 67 |
| 2017 | 32 | 57 |
| 2018 | 37 | 48 |
| 2019 | 29 | 59 |
| 2020 | 41 | 66 |
| 2021 | 38 | 61 |
| 2022 | 27 | 52 |
| 2023 | 21 | 69 |
| 2024 | 21 | 63 |
| 2025 | 26 | 51 |
| 2026 | 15 | 32 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of brain damage18 Aug 2026US 12,708,661 B2Ipsen Biopharm Ltd.
- Treatment of chronic obstructive pulmonary disease using botulinum toxin4 Aug 2026US 12,697,375 B2Penland Foundation
- Therapeutic and cosmetic uses of botulinum neurotoxin serotype E2 Jun 2026US 12,642,842 B2Ipsen Biopharm Ltd.
- Treatment of vestibular vertigo using botulinum toxins26 May 2026US 12,636,343 B2Penland Foundation
- Compositions for the treatment of skin conditions19 May 2026US 12,629,331 B2Dermata Therapeutics, Inc.
- Zonal and targeted methods and uses for treating pain, inflammation, stiffness and arthrofibrosis and balancing muscle forces after total knee arthroplasty (tka)8 Oct 2026US 2026/0306595 A1
- Treatment of pain8 Oct 2026US 2026/0306596 A1Ipsen Biopharm Ltd.
- Treatment methods using botulinum toxins24 Sep 2026US 2026/0284142 A1Penland Foundation
- Injection paradigm for administration of botulinum toxins24 Sep 2026US 2026/0284158 A1Allergan, Inc.
- Injection paradigm for administration of botulinum toxins24 Sep 2026US 2026/0284159 A1Allergan, Inc.
Most cited
By later US patents
- Biodegradable botulinum toxin implant657US 6,506,399 B2Allergan Sales, Inc. · 2003
- Neurotoxin implant376US 6,306,423 B1Allergan Sales, Inc. · 2001
- Treatment of autonomic nerve dysfunction with botulinum toxin359US 5,766,605 AMount Sinai School of Medicine of the City University of New York · 1998
- Clostridial toxin derivatives able to modify peripheral sensory afferent functions318US 5,989,545 AMicrobiological Research Authority · 1999
- Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction274US 5,437,291 A1995